AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
FiercePharma4d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
pharmaphorum4d
Avillion, AstraZeneca asthma rescue treatment given FDA approval
Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...
Pharmabiz3d
US FDA approves AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
Yahoo Finance3d
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
AstraZeneca’s Fasenra (benralizumab ... It initially presents as adult-onset asthma before progressing to multi-organ failure ...
Morningstar4d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca said: “FASENRA is already well established for the treatment of severe eosinophilic asthma, and with this ...
Managed Healthcare Executive3d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...
Medscape3d
Efficacy of Anticholinergic Drugs in Asthma
In the last 5 years, P Paggiaro has received institutional support for educational and research activities from: AstraZeneca ... on top of the current asthma treatment. The first large study ...
London South East4d
AstraZeneca Fasenra treatment for EGPA approved in the US
Ruud Dobber, executive vice president of AstraZeneca's BioPharmaceuticals business unit, said: "Fasenra is already well established for the treatment of severe eosinophilic asthma, and with this ...
EuropaWire4d
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis, Offering New Hope for Patients
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...